Want to join the conversation?
Isaac Ro of Goldman Sachs asks about GRAIL, the new company formed by $ILMN in Jan 2016. CEO Francis deSouza said that the GRAIL team is progressing and it is on track to develop the assay by the end of this year. GRAIL team is also working hard on designing the clinical trial. He added that there are no new updates at this point of time.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.